Wednesday, 06 May 2015 08:00 AM
BOCA RATON, FL / ACCESSSWIRE / May 6, 2015 / LifeTech Capital, a research-focused biotechnology and medical technology investment bank has re- initiated research coverage on Cellular Biomedicine Group (NASDAQ: CBMG) with a Strong Speculative Buy rating and $33.50 price target. The 35-page re-initiation report authored by Stephen M. Dunn, Senior Managing Director of Research at LifeTech Capital discusses Cellular Biomedicine Group's (CBMG) focus on immuno-oncology and stem cell drug development for the domestic China healthcare market.
The report examines recent Phase I/IIa human clinical trial data for their CAR T-Cell (chimeric antigen receptor T-cell) technology targeting CD19+ and CD20+ with their CD30+ and EGFR+/HER1+ data expected later this year. Also discussed is CBMG's recent interim Phase IIb data for their stem cell candidate, ReJoin™, for knee osteoarthritis and cartilage defects as well as pre-clinical indications in Asthma and COPD.
As CBMG shares have declined significantly due to both a sell-off in the biotechnology sector and an anonymous article on SeekingAlpha, Mr. Dunn states, "Despite this, CBMG’s fundamentals remain intact and have, in fact, gotten stronger over the past 5 weeks with additional data for both immuno-oncology and stem cell programs, a NASDAQ uplisting, a U.S. scientific advisory board, additional scientific facilities, $19.6M gross in additional funding and positive events in China and the Sector."
The full re-Initiation Report, including important disclosures, is available for download free of charge at the LifeTech Capital website http://lifetechcapital.com/ltc/?p=4585.
About LifeTech Capital
LifeTech Capital is a multi-disciplinary team of investment professionals specializing in serving the unique needs of the Life Sciences industry and the investor community that serves it. Our institutional research team provides exceptional industry insight into the complex analysis of determining the future value of drugs, devices and the companies and management teams that develop them. LifeTech Capital's investment banking team is extremely knowledgeable in both the Life Sciences and Wall Street with expertise in developing appropriate funding strategies and structures as well as M&A partnering for our clients. Our capital markets team has access to over 400 institutional investors plus a broad base of accredited retail investors through both Newbridge Securities Corporation and investor syndicates. For more information, please see http://www.lifetechcapital.com/.
Securities offered through Newbridge Securities Corporation - Member FINRA/SIPC
About Newbridge Securities Corporation
Newbridge Securities Corporation provides full-service securities brokerage and investment banking services to a broad-based group of individuals and corporate clients. Comprised of a committed and experienced team of approximately 200 financial service professionals, with roughly 80 offices throughout the U.S., representing over $2 Billion in client assets, we seek to empower our clients to build and preserve wealth by providing superior financial services and products. For more information on Newbridge, please visit: http://www.newbridgesecurities.com/.
Please note that LifeTech Capital and Newbridge Securities Corporation specifically disclaim any obligation to issue further press releases for future updates. Future updates, if any, will be available at http://www.lifetechcapital.com/
SOURCE: LifeTech Capital,